Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids
Advanced Science, EarlyView.Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan +19 more
wiley +1 more source
Cancer & MetabolismBackground Lactate dehydrogenase A (LDHA) can regulate tumorigenesis and cancer progression. Nevertheless, whether the regulation of LDHA is involved in the development of gemcitabine resistance in PDAC has not yet been fully elucidated.
Tung-Wei Hsu +11 more
doaj +1 more source
Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis, and chemotherapeutic resistance via accumulation of MCL1 [PDF]
, 2018 学位記番号 ...
Ishii, Norihiro +2 more
core
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. [PDF]
, 2013 Copyright: 2013 Hermann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
A Jemal +37 more
core +4 more sources
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Advanced Science, EarlyView.Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source
Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer. [PDF]
, 2019 BackgroundPancreatic cancer is one of the most lethal malignancies due to frequent late diagnosis, aggressive tumor growth and metastasis formation.
Horne, David A +4 more
core +1 more source
Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine. [PDF]
, 2019 Most pancreatic cancers are usually diagnosed at an advanced stage when they have already metastasized. Epigallocatechin-3-gallate (EGCG), a major polyphenolic constituent of green tea, has been shown to reduce pancreatic cancer growth, but its effect on
Hackman, Robert M +4 more
core +2 more sources
Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer [PDF]
British Journal of Cancer, 2006 Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS >or=50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and ...
Reni M +15 more
openaire +2 more sources
Advanced Science, EarlyView.Peptide dendrimer–based nanoplatform with mitochondria‐targeting capability was developed for synergistic chemo‐photothermal therapy. The system promotes efficient transcytosis, induces mitochondrial dysfunction, triggers immunogenic cell death (ICD), and enhance antitumor immunity by promoting dendritic cell maturation and T‐cell activation, resulting
Min Li +15 more
wiley +1 more source
PLoS ONEGemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh +6 more
doaj +1 more source